{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T09:12:12Z","timestamp":1793697132464,"version":"4.5.1"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:00:00Z","timestamp":1620950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["138116"],"award-info":[{"award-number":["138116"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["163297"],"award-info":[{"award-number":["163297"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013362","name":"Swiss Cancer Research Foundation","doi-asserted-by":"publisher","award":["KFS-4461-02-2018"],"award-info":[{"award-number":["KFS-4461-02-2018"]}],"id":[{"id":"10.13039\/501100013362","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The development of rational combination therapies is key to overcome inherent treatment resistance of glioblastoma (GBM). We aim at identifying new druggable targets by disturbing GBM cells with inhibitors of bromodomain and extra-terminal motif (BET) proteins to reveal cancer-relevant vulnerabilities that may sensitize to a second drug. BET proteins are epigenetic modulators and have been associated with proto-oncogene overexpression in cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A GBM-derived sphere-line was treated with the BET inhibitor (BETi) JQ1 over a time-course of 48 hours, followed by RNA-sequencing. Four chromatin marks were investigated by chromatin immunoprecipitation followed by sequencing (ChIP-seq). Signatures of interest were functionally validated in vitro and in orthotopic xenografts. Combination therapies were evaluated for synergistic effects.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Cancer-relevant pathways significantly modulated by JQ1 comprised interferon alpha (IFN-\u03b1) response genes and response signatures to histone deacetylase inhibitors (HDACi). The IFN-signature was reminiscent of a GBM-derived IFN-signature comprising CD274 (PD-L1). Functional pathway analysis suggested that JQ1 was acting directly on the transcriptional level of IFN-response genes and not via the canonical JAK\/STAT pathway. This was in line with JQ1 modulated expression and BRD4 and Pol II occupancy at IFN-signature genes, supporting a direct mechanistic interaction. Finally, we showed that combining HDACi with JQ1 acts synergistically in reducing cell viability of GS-lines.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our approach identified BETi-induced vulnerabilities in cancer-relevant pathways, potentially amenable to synergistic combinatorial therapy, such as combination with HDACi. The direct inhibitory effect of BETi on IFN-responsive genes in GBM cells, including CD274, indicates modulation of the tumor immune landscape and warrants further studies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/neuonc\/noab115","type":"journal-article","created":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T14:31:32Z","timestamp":1620743492000},"page":"1680-1692","source":"Crossref","is-referenced-by-count":41,"title":["BET inhibitors repress expression of interferon-stimulated genes and synergize with HDAC inhibitors in glioblastoma"],"prefix":"10.1093","volume":"23","author":[{"given":"Olga","family":"Gusyatiner","sequence":"first","affiliation":[{"name":"Neuroscience Research Centre, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland"},{"name":"Service of Neurosurgery, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland"},{"name":"Swiss Cancer Center L\u00e9man (SCCL), Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1398-4689","authenticated-orcid":false,"given":"Pierre","family":"Bady","sequence":"additional","affiliation":[{"name":"Neuroscience Research Centre, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland"},{"name":"Service of Neurosurgery, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland"},{"name":"Bioinformatics Core Facility, SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland"},{"name":"Swiss Cancer Center L\u00e9man (SCCL), Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minh D T","family":"Pham","sequence":"additional","affiliation":[{"name":"Neuroscience Research Centre, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Lei","sequence":"additional","affiliation":[{"name":"Neuroscience Research Centre, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jungyeon","family":"Park","sequence":"additional","affiliation":[{"name":"Neuroscience Research Centre, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy T","family":"Daniel","sequence":"additional","affiliation":[{"name":"Service of Neurosurgery, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Delorenzi","sequence":"additional","affiliation":[{"name":"Bioinformatics Core Facility, SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland"},{"name":"Department of Oncology, University of Lausanne, Lausanne, Switzerland"},{"name":"Swiss Cancer Center L\u00e9man (SCCL), Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0855-6495","authenticated-orcid":false,"given":"Monika E","family":"Hegi","sequence":"additional","affiliation":[{"name":"Service of Neurosurgery, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland"},{"name":"Swiss Cancer Center L\u00e9man (SCCL), Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,5,14]]},"reference":[{"issue":"23","key":"2021100111121638400_CIT0001","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA."},{"issue":"8","key":"2021100111121638400_CIT0002","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","article-title":"Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions","volume":"22","author":"Wen","year":"2020","journal-title":"Neuro Oncol."},{"issue":"1","key":"2021100111121638400_CIT0003","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13059-020-02085-1","article-title":"Single-cell lineage analysis reveals genetic and epigenetic interplay in glioblastoma drug resistance","volume":"21","author":"Eyler","year":"2020","journal-title":"Genome Biol."},{"issue":"5","key":"2021100111121638400_CIT0004","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ccell.2020.08.008","article-title":"Epigenomic reprogramming as a driver of malignant glioma","volume":"38","author":"Phillips","year":"2020","journal-title":"Cancer Cell."},{"issue":"7153","key":"2021100111121638400_CIT0005","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nature06008","article-title":"Genome-wide maps of chromatin state in pluripotent and lineage-committed cells","volume":"448","author":"Mikkelsen","year":"2007","journal-title":"Nature."},{"issue":"7205","key":"2021100111121638400_CIT0006","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/nature07107","article-title":"Genome-scale DNA methylation maps of pluripotent and differentiated cells","volume":"454","author":"Meissner","year":"2008","journal-title":"Nature."},{"issue":"7697","key":"2021100111121638400_CIT0007","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nature26000","article-title":"DNA methylation-based classification of central nervous system tumours","volume":"555","author":"Capper","year":"2018","journal-title":"Nature."},{"issue":"3","key":"2021100111121638400_CIT0008","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jmoldx.2015.11.009","article-title":"Sensitivity analysis of the MGMT-STP27 model and impact of genetic and epigenetic context to predict the MGMT methylation status in gliomas and other tumors","volume":"18","author":"Bady","year":"2016","journal-title":"J Mol Diagn."},{"issue":"6","key":"2021100111121638400_CIT0009","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1158\/1078-0432.CCR-18-3181","article-title":"MGMT promoter methylation cutoff with safety margin for selecting glioblastoma patients into trials omitting temozolomide: a pooled analysis of four clinical trials","volume":"25","author":"Hegi","year":"2019","journal-title":"Clin Cancer Res."},{"issue":"5","key":"2021100111121638400_CIT0010","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/15592294.2016.1265710","article-title":"Bromodomain inhibitors and cancer therapy: from structures to applications","volume":"12","author":"P\u00e9rez-Salvia","year":"2017","journal-title":"Epigenetics."},{"issue":"2","key":"2021100111121638400_CIT0011","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell."},{"issue":"9","key":"2021100111121638400_CIT0012","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1002\/ijc.30256","article-title":"OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models","volume":"139","author":"Berenguer-Daiz\u00e9","year":"2016","journal-title":"Int J Cancer."},{"issue":"7","key":"2021100111121638400_CIT0013","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1158\/1078-0432.CCR-12-3066","article-title":"Inhibition of BET bromodomain targets genetically diverse glioblastoma","volume":"19","author":"Cheng","year":"2013","journal-title":"Clin Cancer Res."},{"issue":"4","key":"2021100111121638400_CIT0014","doi-asserted-by":"crossref","first-page":"611","DOI":"10.4161\/epi.27906","article-title":"BET bromodomain proteins are required for glioblastoma cell proliferation","volume":"9","author":"Pastori","year":"2014","journal-title":"Epigenetics."},{"key":"2021100111121638400_CIT0015","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.semcancer.2017.11.010","article-title":"Glioma epigenetics: from subclassification to novel treatment options","volume":"51","author":"Gusyatiner","year":"2018","journal-title":"Semin Cancer Biol."},{"issue":"4","key":"2021100111121638400_CIT0016","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.cell.2012.06.045","article-title":"Small-molecule inhibition of BRDT for male contraception","volume":"150","author":"Matzuk","year":"2012","journal-title":"Cell."},{"issue":"2","key":"2021100111121638400_CIT0017","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1158\/1078-0432.CCR-10-1931","article-title":"Extent and patterns of MGMT promoter methylation in glioblastoma- and respective glioblastoma-derived spheres","volume":"17","author":"Sciuscio","year":"2011","journal-title":"Clin Cancer Res."},{"key":"2021100111121638400_CIT0018","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13059-015-0583-7","article-title":"Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma","volume":"16","author":"Kurscheid","year":"2015","journal-title":"Genome Biol."},{"issue":"6","key":"2021100111121638400_CIT0019","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/neuonc\/nos072","article-title":"DNA fingerprinting of glioma cell lines and considerations on similarity measurements","volume":"14","author":"Bady","year":"2012","journal-title":"Neuro Oncol."},{"issue":"13","key":"2021100111121638400_CIT0020","first-page":"4978","article-title":"Loss of focal adhesion kinase (FAK) inhibits epidermal growth factor receptor-dependent migration and induces aggregation of nh(2)-terminal FAK in the nuclei of apoptotic glioblastoma cells","volume":"61","author":"Jones","year":"2001","journal-title":"Cancer Res."},{"issue":"1","key":"2021100111121638400_CIT0021","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/onc.2015.61","article-title":"WIF1 re-expression in glioblastoma inhibits migration through attenuation of non-canonical WNT signaling by downregulating the lncRNA MALAT1","volume":"35","author":"Vassallo","year":"2016","journal-title":"Oncogene."},{"key":"2021100111121638400_CIT0022","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","article-title":"Searching for drug synergy in complex dose-response landscapes using an interaction potency model","volume":"13","author":"Yadav","year":"2015","journal-title":"Comput Struct Biotechnol J."},{"key":"2021100111121638400_CIT0023","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.csbj.2017.07.003","article-title":"Corrigendum to \u201cSearching for drug synergy in complex dose-response landscapes using an interaction potency model\u201d [Comput. Struct. Biotechnol. J. 13 (2015) 504\u2013513]","volume":"15","author":"Yadav","year":"2017","journal-title":"Comput Struct Biotechnol J"},{"key":"2021100111121638400_CIT0024","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/978-1-4939-7493-1_17","article-title":"Methods for high-throughput drug combination screening and synergy scoring","volume":"1711","author":"He","year":"2018","journal-title":"Methods Mol Biol"},{"issue":"11","key":"2021100111121638400_CIT0025","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/carcin\/bgv124","article-title":"Autophagy-mediated degradation of nuclear envelope proteins during oncogene-induced senescence","volume":"36","author":"Lenain","year":"2015","journal-title":"Carcinogenesis."},{"issue":"1","key":"2021100111121638400_CIT0026","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1890\/0012-9658(2001)082[0290:FMMTCD]2.0.CO;2","article-title":"Fitting multivariate models to community data: a comment on distance-based redundancy analysis","volume":"82","author":"McArdle","year":"2001","journal-title":"Ecology"},{"issue":"1","key":"2021100111121638400_CIT0027","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0167-9473(94)90135-X","article-title":"Multiple factor analysis (AFMULT package)","volume":"18","author":"Escofier","year":"1994","journal-title":"Comput Stat Data Anal"},{"key":"2021100111121638400_CIT0028","volume-title":"A language and environment for statistical computing","author":"R Core Team","year":"2015"},{"issue":"10","key":"2021100111121638400_CIT0029","doi-asserted-by":"crossref","first-page":"R80","DOI":"10.1186\/gb-2004-5-10-r80","article-title":"Bioconductor: open software development for computational biology and bioinformatics","volume":"5","author":"Gentleman","year":"2004","journal-title":"Genome Biol."},{"key":"2021100111121638400_CIT0030","doi-asserted-by":"crossref","first-page":"750","DOI":"10.2307\/2529140","article-title":"Le traitement des variables vectorielles","volume":"29","author":"Escoufier","year":"1973","journal-title":"Biometrics"},{"issue":"1","key":"2021100111121638400_CIT0031","first-page":"5","article-title":"The ade4 package - I: One-table methods","volume":"4","author":"Chessel","year":"2004","journal-title":"R News"},{"issue":"6","key":"2021100111121638400_CIT0032","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell."},{"issue":"16","key":"2021100111121638400_CIT0033","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1158\/1078-0432.CCR-18-0260","article-title":"Combined HDAC and bromodomain protein inhibition reprograms tumor cell metabolism and elicits synthetic lethality in glioblastoma","volume":"24","author":"Zhang","year":"2018","journal-title":"Clin Cancer Res."},{"issue":"4","key":"2021100111121638400_CIT0034","first-page":"879","article-title":"Bromodomain inhibitor jq1 induces cell cycle arrest and apoptosis of glioma stem cells through the VEGF\/PI3K\/AKT signaling pathway","volume":"55","author":"Wen","year":"2019","journal-title":"Int J Oncol."},{"issue":"18","key":"2021100111121638400_CIT0035","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2007.15.7164","article-title":"Stem cell-related \u201cself-renewal\u201d signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma","volume":"26","author":"Murat","year":"2008","journal-title":"J Clin Oncol."},{"issue":"3","key":"2021100111121638400_CIT0036","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/biomet\/93.3.491","article-title":"Adaptive linear step-up procedures that control the false discovery rate","volume":"93","author":"Benjamini","year":"2006","journal-title":"Biometrika"},{"issue":"1","key":"2021100111121638400_CIT0037","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/ng.3167","article-title":"What are super-enhancers?","volume":"47","author":"Pott","year":"2015","journal-title":"Nat Genet."},{"issue":"2","key":"2021100111121638400_CIT0038","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","article-title":"Selective inhibition of tumor oncogenes by disruption of super-enhancers","volume":"153","author":"Lov\u00e9n","year":"2013","journal-title":"Cell."},{"issue":"2","key":"2021100111121638400_CIT0039","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/1535-7163.MCT-16-0475","article-title":"HEXIM1 as a robust pharmacodynamic marker for monitoring target engagement of BET family bromodomain inhibitors in tumors and surrogate tissues","volume":"16","author":"Lin","year":"2017","journal-title":"Mol Cancer Ther."},{"issue":"1","key":"2021100111121638400_CIT0040","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/0008-5472.CAN-07-2531","article-title":"Genome-wide transcriptional response to 5-aza-2\u2032-deoxycytidine and trichostatin A in multiple myeloma cells","volume":"68","author":"Heller","year":"2008","journal-title":"Cancer Res."},{"issue":"2","key":"2021100111121638400_CIT0041","doi-asserted-by":"crossref","first-page":"pkz092","DOI":"10.1093\/jncics\/pkz092","article-title":"How much can we bet on activity of BET inhibitors beyond NUT-midline carcinoma?","volume":"4","author":"Martin-Romano","year":"2020","journal-title":"JNCI Cancer Spectr."},{"issue":"2","key":"2021100111121638400_CIT0042","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-019-0267-4","article-title":"Combining epigenetic drugs with other therapies for solid tumours - past lessons and future promise","volume":"17","author":"Morel","year":"2020","journal-title":"Nat Rev Clin Oncol."},{"issue":"22","key":"2021100111121638400_CIT0043","doi-asserted-by":"crossref","first-page":"E5086","DOI":"10.1073\/pnas.1712363115","article-title":"Targetable BET proteins- and E2F1-dependent transcriptional program maintains the malignancy of glioblastoma","volume":"115","author":"Xu","year":"2018","journal-title":"Proc Natl Acad Sci USA."},{"issue":"1","key":"2021100111121638400_CIT0044","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1038\/s41467-018-04315-4","article-title":"Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles","volume":"9","author":"Lam","year":"2018","journal-title":"Nat Commun."},{"issue":"1","key":"2021100111121638400_CIT0045","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41467-020-20400-z","article-title":"BET inhibition disrupts transcription but retains enhancer-promoter contact","volume":"12","author":"Crump","year":"2021","journal-title":"Nat Commun."},{"issue":"8","key":"2021100111121638400_CIT0046","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1093\/neuonc\/nou307","article-title":"Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma","volume":"17","author":"Berghoff","year":"2015","journal-title":"Neuro Oncol."},{"issue":"1","key":"2021100111121638400_CIT0047","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ccell.2017.06.003","article-title":"Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment","volume":"32","author":"Wang","year":"2017","journal-title":"Cancer Cell"},{"issue":"9","key":"2021100111121638400_CIT0048","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.celrep.2017.02.011","article-title":"BET-bromodomain inhibitors engage the host immune system and regulate expression of the immune checkpoint ligand PD-L1","volume":"18","author":"Hogg","year":"2017","journal-title":"Cell Rep."},{"issue":"7","key":"2021100111121638400_CIT0049","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.jid.2018.12.024","article-title":"BET inhibition modifies melanoma infiltrating T cells and enhances response to PD-L1 Blockade","volume":"139","author":"Nikbakht","year":"2019","journal-title":"J Invest Dermatol."},{"issue":"4","key":"2021100111121638400_CIT0050","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ccell.2020.08.005","article-title":"Conserved interferon-gamma signaling drives clinical response to immune checkpoint blockade therapy in melanoma","volume":"38","author":"Grasso","year":"2020","journal-title":"Cancer Cell"},{"issue":"10","key":"2021100111121638400_CIT0051","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/nm.3952","article-title":"Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma","volume":"21","author":"Mazur","year":"2015","journal-title":"Nat Med."},{"issue":"4","key":"2021100111121638400_CIT0052","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/neuonc\/nox161","article-title":"Phase I\/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874\/ABTC 02","volume":"20","author":"Galanis","year":"2018","journal-title":"Neuro Oncol."},{"issue":"2","key":"2021100111121638400_CIT0053","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/neuonc\/nor198","article-title":"Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study","volume":"14","author":"Friday","year":"2012","journal-title":"Neuro Oncol."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noab115\/38701448\/noab115.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/23\/10\/1680\/40493876\/noab115.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/23\/10\/1680\/40493876\/noab115.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T17:01:24Z","timestamp":1633107684000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/23\/10\/1680\/6275457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,14]]},"references-count":53,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,5,14]]},"published-print":{"date-parts":[[2021,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noab115","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,1]]},"published":{"date-parts":[[2021,5,14]]}}}